The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial

The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial

DSpace/Manakin Repository

The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial

dc.contributor.author	Pater, J.
dc.contributor.author	Richardson, H
dc.contributor.author	Johnston, D.
dc.contributor.author	Goss, Paul E.
dc.date.accessioned	2011-03-11T20:53:52Z
dc.date.issued	2007
dc.identifier.citation	Richardson, H., D. Johnston, J. Pater, and Paul E. Goss. 2007. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Current Oncology 14(3): 89-96.	en_US
dc.identifier.issn	1198-0052	en_US
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:4741070
dc.description.abstract	Several large phase iii trials have demonstrated that tamoxifen—and more recently, raloxifene—can effectively reduce the incidence of invasive breast cancer by 50%. However, these selective estrogen receptor modulators can also be associated with several rare, but serious, adverse events. Recently, the third-generation aromatase inhibitors (AIS) have demonstrated excellent efficacy in adjuvant breast cancer trials, and they show particular promise in the breast cancer prevention setting. The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) has developed a randomized phase iii study to determine the efficacy of an ai (exemestane) to reduce the incidence of invasive breast cancer in postmenopausal women at an increased risk for developing breast cancer. The ncic ctg map.3 (ExCel) trial is a double-blind placebo-controlled multicentre, multinational trial. Based on the known preclinical and clinical profile of the ais, a greater reduction in breast cancer incidence with fewer side effects is hypothesized with this class of agents than with tamoxifen or raloxifene.	en_US
dc.language.iso	en_US	en_US
dc.publisher	Multimed Inc.	en_US
dc.relation.hasversion	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1899358/pdf/	en_US
dash.license	LAA
dc.subject	aromatase inhibitors	en_US
dc.subject	breast cancer risk reduction	en_US
dc.subject	chemoprevention	en_US
dc.title	The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial	en_US
dc.type	Journal Article	en_US
dc.description.version	Version of Record	en_US
dc.relation.journal	Current Oncology	en_US
dash.depositing.author	Goss, Paul E.
dc.date.available	2011-03-11T20:53:52Z
dash.affiliation.other	HMS^Medicine-Massachusetts General Hospital	en_US